A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study

Descripción del Articulo

Delafloxacin es una fluoroquinolona intravenosa (IV)/oral con actividad sobre los organismos anaeróbicos gram-positivos, gram-negativos, atípicos, incluyendo el Staphylococcus aureus resistente a methicillin. Este estudio compara el uso de delafloxacin 300 mg IV cada 12 horas por 3 días con un cambi...

Descripción completa

Detalles Bibliográficos
Autores: Cruz-Saldariaga, María, O’Riordan, William, McManus, Alison, Teras, Juri, Quintas, Megan, Lawrence, Laura, ShuJui Liang, Cammarata, Sue
Formato: artículo
Fecha de Publicación:2018
Institución:Seguro Social de Salud
Repositorio:ESSALUD-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.essalud.gob.pe:20.500.12959/101
Enlace del recurso:https://hdl.handle.net/20.500.12959/101
Nivel de acceso:acceso abierto
Materia:Farmacología y Farmacia
Enfermedades de la piel
https://purl.org/pe-repo/ocde/ford#3.05.00
id ESSA_a631022664f805346c386c90db7b58a5
oai_identifier_str oai:repositorio.essalud.gob.pe:20.500.12959/101
network_acronym_str ESSA
network_name_str ESSALUD-Institucional
repository_id_str 4277
dc.title.es_PE.fl_str_mv A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
title A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
spellingShingle A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
Cruz-Saldariaga, María
Farmacología y Farmacia
Enfermedades de la piel
https://purl.org/pe-repo/ocde/ford#3.05.00
title_short A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
title_full A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
title_fullStr A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
title_full_unstemmed A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
title_sort A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
author Cruz-Saldariaga, María
author_facet Cruz-Saldariaga, María
O’Riordan, William
McManus, Alison
Teras, Juri
Quintas, Megan
Lawrence, Laura
ShuJui Liang
Cammarata, Sue
author_role author
author2 O’Riordan, William
McManus, Alison
Teras, Juri
Quintas, Megan
Lawrence, Laura
ShuJui Liang
Cammarata, Sue
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Cruz-Saldariaga, María
O’Riordan, William
McManus, Alison
Teras, Juri
Quintas, Megan
Lawrence, Laura
ShuJui Liang
Cammarata, Sue
dc.subject.es_PE.fl_str_mv Farmacología y Farmacia
Enfermedades de la piel
topic Farmacología y Farmacia
Enfermedades de la piel
https://purl.org/pe-repo/ocde/ford#3.05.00
dc.subject.ocde.es_PE.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.05.00
description Delafloxacin es una fluoroquinolona intravenosa (IV)/oral con actividad sobre los organismos anaeróbicos gram-positivos, gram-negativos, atípicos, incluyendo el Staphylococcus aureus resistente a methicillin. Este estudio compara el uso de delafloxacin 300 mg IV cada 12 horas por 3 días con un cambio a 450 mg oral, a vancomycin 15 mg/kg IV con aztreonam por 5–14 días, en Infecciones bacterianas agudas y de estructura de la piel. Se observó la respuesta en 48–72 horas y en 21 a 28 días.
publishDate 2018
dc.date.accessioned.none.fl_str_mv 2019-03-29T16:01:48Z
dc.date.available.none.fl_str_mv 2019-03-29T16:01:48Z
dc.date.issued.fl_str_mv 2018
dc.type.es_PE.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.citation.es_PE.fl_str_mv Clinical Infectious Diseases
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.12959/101
identifier_str_mv Clinical Infectious Diseases
url https://hdl.handle.net/20.500.12959/101
dc.language.iso.es_PE.fl_str_mv eng
language eng
dc.rights.es_PE.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.es_PE.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.es_PE.fl_str_mv application/pdf
dc.publisher.es_PE.fl_str_mv Seguro Social de Salud (EsSalud)
dc.publisher.country.es_PE.fl_str_mv PE
dc.source.es_PE.fl_str_mv Seguro Social de Salud (EsSalud)
Repositorio Institucional EsSalud
dc.source.none.fl_str_mv reponame:ESSALUD-Institucional
instname:Seguro Social de Salud
instacron:ESSALUD
instname_str Seguro Social de Salud
instacron_str ESSALUD
institution ESSALUD
reponame_str ESSALUD-Institucional
collection ESSALUD-Institucional
bitstream.url.fl_str_mv https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/1/A%20Comparison%20of%20the%20Efficacy%20and%20Safety%20of%20Intravenous%20Followed%20by%20Oral%20Delafloxacin%20with%20Vancomycin%20Plus%20Aztreonam%20for%20the.pdf
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/2/license.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/3/A%20Comparison%20of%20the%20Efficacy%20and%20Safety%20of%20Intravenous%20Followed%20by%20Oral%20Delafloxacin%20with%20Vancomycin%20Plus%20Aztreonam%20for%20the.pdf.txt
https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/4/A%20Comparison%20of%20the%20Efficacy%20and%20Safety%20of%20Intravenous%20Followed%20by%20Oral%20Delafloxacin%20with%20Vancomycin%20Plus%20Aztreonam%20for%20the.pdf.jpg
bitstream.checksum.fl_str_mv 84697a0fa71091bb204c1addcb7d6c53
8a4605be74aa9ea9d79846c1fba20a33
01bc961028f1092d2ec10e6c1857a0f3
12e375c432672bdffade6769414f457b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Seguro Social de Salud – ESSALUD
repository.mail.fl_str_mv bibliotecacentral@essalud.gob.pe
_version_ 1813537097905078272
spelling Cruz-Saldariaga, MaríaO’Riordan, WilliamMcManus, AlisonTeras, JuriQuintas, MeganLawrence, LauraShuJui LiangCammarata, Sue2019-03-29T16:01:48Z2019-03-29T16:01:48Z2018Clinical Infectious Diseaseshttps://hdl.handle.net/20.500.12959/101Delafloxacin es una fluoroquinolona intravenosa (IV)/oral con actividad sobre los organismos anaeróbicos gram-positivos, gram-negativos, atípicos, incluyendo el Staphylococcus aureus resistente a methicillin. Este estudio compara el uso de delafloxacin 300 mg IV cada 12 horas por 3 días con un cambio a 450 mg oral, a vancomycin 15 mg/kg IV con aztreonam por 5–14 días, en Infecciones bacterianas agudas y de estructura de la piel. Se observó la respuesta en 48–72 horas y en 21 a 28 días.application/pdfengSeguro Social de Salud (EsSalud)PEinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/4.0/Seguro Social de Salud (EsSalud)Repositorio Institucional EsSaludreponame:ESSALUD-Institucionalinstname:Seguro Social de Saludinstacron:ESSALUDFarmacología y FarmaciaEnfermedades de la pielhttps://purl.org/pe-repo/ocde/ford#3.05.00A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized studyinfo:eu-repo/semantics/articleORIGINALA Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the.pdfA Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the.pdfapplication/pdf948744https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/1/A%20Comparison%20of%20the%20Efficacy%20and%20Safety%20of%20Intravenous%20Followed%20by%20Oral%20Delafloxacin%20with%20Vancomycin%20Plus%20Aztreonam%20for%20the.pdf84697a0fa71091bb204c1addcb7d6c53MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52TEXTA Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the.pdf.txtA Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the.pdf.txtExtracted texttext/plain49082https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/3/A%20Comparison%20of%20the%20Efficacy%20and%20Safety%20of%20Intravenous%20Followed%20by%20Oral%20Delafloxacin%20with%20Vancomycin%20Plus%20Aztreonam%20for%20the.pdf.txt01bc961028f1092d2ec10e6c1857a0f3MD53THUMBNAILA Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the.pdf.jpgA Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin with Vancomycin Plus Aztreonam for the.pdf.jpgGenerated Thumbnailimage/jpeg9040https://repositorio.essalud.gob.pe/bitstream/20.500.12959/101/4/A%20Comparison%20of%20the%20Efficacy%20and%20Safety%20of%20Intravenous%20Followed%20by%20Oral%20Delafloxacin%20with%20Vancomycin%20Plus%20Aztreonam%20for%20the.pdf.jpg12e375c432672bdffade6769414f457bMD5420.500.12959/101oai:repositorio.essalud.gob.pe:20.500.12959/1012022-09-09 03:01:23.833Repositorio Seguro Social de Salud – ESSALUDbibliotecacentral@essalud.gob.peTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo=
score 13.936249
A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares